| DIRECT COMPETITOR COMPARISON | |
| SNSS | AZN | Pvt1 | VION.OB | Industry | | Market Cap: | 14.20M | 67.35B | N/A | 6.64M | 98.96M | | Employees: | 36 | 65,000 | N/A | 43 | 68 | | Qtrly Rev Growth (yoy): | -97.60% | 5.50% | N/A | -37.50% | 19.70% | | Revenue (ttm): | 3.76M | 32.05B | N/A | 23.00K | 14.01M | | Gross Margin (ttm): | N/A | 82.24% | N/A | N/A | 65.67% | | EBITDA (ttm): | -19.61M | 13.52B | N/A | -19.49M | -12.30M | | Oper Margins (ttm): | -531.78% | 37.85% | N/A | -86,021.74% | -137.11% | | Net Income (ttm): | -69.49M | 7.22B | N/A | -24.05M | N/A | | EPS (ttm): | -2.019 | 4.98 | N/A | -3.067 | -0.33 | | P/E (ttm): | N/A | 9.33 | N/A | N/A | 17.26 | | PEG (5 yr expected): | N/A | N/A | N/A | N/A | 1.28 | | P/S (ttm): | 3.82 | 2.09 | N/A | 317.74 | 9.45 |
|
| BIOTECHNOLOGY COMPANIES RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Amgen Inc. | AMGN | 56.90 | 0.09% | 57.59B | 12.41 | | Genentech, Inc. | Private - View Profile | | Biogen Idec Inc. | BIIB | 48.28 | 0.21% | 13.96B | 16.16 | | Genzyme Corp. | GENZ | 50.23 | 0.50% | 13.33B | 28.64 | | Merck Serono S.A. | Private - View Profile | | Chiron Corporation | Private - View Profile | | Gilead Sciences Inc. | GILD | 46.795 | 0.44% | 42.11B | 18.10 | | MedImmune, Inc. | Private - View Profile | | Life Technologies Corporation | LIFE | 50.71 | 0.14% | 9.04B | 1034.90 | | Teva Pharmaceutical Industries Limited | TEVA | 53.6525 | -0.66% | 47.27B | 49.09 |
|
| GENERIC DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Sandoz International GmbH | Private - View Profile | | Watson Pharmaceuticals Inc. | WPI | 38.21 | 0.82% | 4.06B | 19.70 | | King Pharmaceuticals Inc. | KG | 11.595 | -1.07% | 2.88B | N/A | | Ranbaxy Laboratories Limited | Private - View Profile | | Mylan, Inc. | MYL | 18.26 | 1.50% | 5.58B | 112.02 | | Pfizer Inc. | PFE | 18.440001 | -0.27% | 148.80B | 15.32 | | Johnson & Johnson | JNJ | 64.45 | 0.14% | 177.82B | 14.08 | | GlaxoSmithKline plc | GSK | 42.68 | -0.16% | 108.19B | 13.46 | | Sanofi-Aventis | SNY | 38.86 | -1.32% | 101.47B | N/A | | Novartis AG | NVS | 55.73 | 0.32% | 126.57B | 16.69 |
|
| DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | RHHBY.PK | 41.37 | -0.12% | N/A | N/A | | AstraZeneca plc | AZN | 46.45 | 0.32% | 67.35B | 9.33 | | Abbott Laboratories | ABT | 53.94 | 0.30% | 83.43B | 14.61 | | Bristol-Myers Squibb Co. | BMY | 25.77 | 2.51% | 51.05B | 13.33 |
|
| NEWS ON DIRECT COMPETITORS | |
| | AZN | | Bristol Seeks EU OK for Apixaban Mon 10:06am -
Zacks.com | | | AZN | | Blood Thinner Battle Heats Up Sun 1:36pm -
at Forbes.com | | | AZN | | Astra-Zeneca Flies to JUPITER on Drug Results Sun 9:04am -
at Seeking Alpha | | | AZN | | [$$] Seroquel XR Gets New FDA Approval Fri, Dec 4 -
at The Wall Street Journal Online | | | AZN | | Week Ahead: Road Upward for Stocks Is Getting Rougher Fri, Dec 4 -
at CNBC | | | AZN | | Antipsychotics, Diabetes & Kids Fri, Dec 4 -
at The Wall Street Journal Online | | | AZN | | Baxter Receives H1N1 Vaccine Order Fri, Dec 4 -
Zacks.com | | | AZN | | Significant Deal for AZN Fri, Dec 4 -
Zacks.com | | | AZN | | After Rising 500%, What Did You Expect? Fri, Dec 4 -
at Motley Fool | | | AZN | | FDA Panel Recommends Antipsychotic-Drug Review of Kids' Weight Gain Fri, Dec 4 -
at The Wall Street Journal Online | | | AZN | | Biotech Stocks: Euro drugmakers lead sector stocks higher Fri, Dec 4 -
at MarketWatch | | | VION.OB | | Biotech Stock Mailbag: Hemispherx Biopharma Fri, Dec 4 -
at TheStreet.com | | | VION.OB | | VION PHARMACEUTICALS INC Files SEC form 8-K, Costs Associated with Exit or Disposal Activities Tue, Nov 24 -
EDGAR Online | | | VION.OB | | VION PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition Mon, Nov 16 -
EDGAR Online | | | VION.OB | | VION PHARMACEUTICALS INC Financials Sat, Nov 14 -
EDGAR Online Financials | | | VION.OB | | Vion Pharmaceuticals Earnings Call scheduled for 8:30 am ET today Thu, Nov 12 -
CCBN | | | All Headlines for these symbols... |
|
|
|